Key Investment Considerations:
- First-in-Class Technology — VCool™ a Targeted Temperature Management (TTM) device for cooling and warming for intensive care and OR markets.
- Secret Sauce – Cool air/gas that is tolerable in an awake patient: Only TTM device that can cool an awake patient to reduce sedative and paralytic pharmaceuticals.
- Huge Market – The TTM cooling and warming market in the US is $1.5B in annual sales. The global market has $3.5B in annual sales. VCool™ positioned as first-line therapy for Stroke, Sudden Cardiac Arrests, and Traumatic Brain Injury patients.
- World Class Management Team: Founder has been COO for two global industry leaders with experience in; regulatory, quality management, clinical trials, FDA submission, product development, national GPO and IDN contracts, and strong working relationships with KOLs in the TTM market
- Revenue Model — Capital device with recurring disposable revenue with 80% product margins for profitable company to exit to strategics: Stryker, BD, Teleflex, Zoll, Belmont Medical. VCool™ is a cost reduction for hospitals at a fourth of the costs of the market leader.
Impressive Traction:
- Funding: NeuroIntact raised $1.25M to date.
- Successful animal studies completed meeting safety and efficacy endpoints.
- Clinical Site Selection: The University of Maryland has committed for the first human feasibility clinical trial site with a world renown Principal Investigator who has focused on targeted temperature management that optimizes brain temperature while minimizing systemic effects.
- IP development.
- VCool™ device ready for human trial.
Agenda:
6:30pm – Open Bar and Happy Hour
7:00 pm – 8:30pm – Networking, Dinner, and Presentation
To reserve your space, RSVP to Marc McKenna at: mmckenna@neurointact.com
We will provide a confirmation email and a calendar invitation after you register.
We look forward to seeing you June 25th,
NeuroIntact and Neuvation
